Genotype-Guided SSRI Prescribing Shows No Short-Term Benefit but Higher Remission at 6 Months

This randomized clinical trial investigated whether genotype-guided prescribing of selective serotonin reuptake inhibitors (SSRIs) improves outcomes compared with usual care in patients with depression. The study enrolled 1460 patients aged 8 years or older who had been depressed for 3 months or longer. Participants were recruited from primary care, psychiatry, or family medicine clinics at enrolling sites throughout the US. The intervention involved using pharmacogenetic information to guide SSRI selection and dosing, while the comparator was usual care without genetic guidance. The primary outcome was change in Patient-Reported Outcomes Measurement Information System (PROMIS) depression T scores at 3 months among patients with the actionable phenotype. Secondary outcomes included adverse effect severity of SSRIs at 3 months and depression remission at 6 months, measured using PROMIS depression scores and Patient Health Questionnaire-8 (PHQ-8) scores.

At 3 months, the primary outcome showed no significant difference between groups. The mean (SD) change in PROMIS depression T scores was -4.3 (8.4) in the intervention group versus -4.0 (8.1) in the usual care group (P = .68). Similarly, medication adverse effect burden at 3 months did not differ significantly, with mean (SD) changes of 8.2 (4.3) versus 7.8 (4.5) (P = .37). PHQ-8 score change at 3 months also showed no significant difference: -3.3 (5.2) versus -2.7 (4.8) (P = .13).

However, at 6 months, the PROMIS depression T-score remission rate was higher in the intervention group compared with the usual care group: 48.3% (153 of 317 patients) versus 39.4% (122 of 310 patients) (P = .02). This secondary outcome suggests a potential longer-term benefit of genotype-guided prescribing, though the primary endpoint was negative.

Safety data were limited. Adverse effect severity of SSRIs at 3 months was reported as mean (SD) change of 8.2 (4.3) versus 7.8 (4.5), with no significant difference. Serious adverse events, discontinuations, and tolerability were not reported.

These results contrast with some prior studies that have suggested pharmacogenetic testing may improve depression outcomes, but many of those were smaller or had methodological differences. The current trial is larger and more rigorous, but its negative primary outcome tempers enthusiasm. The positive secondary finding at 6 months should be interpreted cautiously, as it was not the primary endpoint and could be due to chance.

Key methodological limitations include the lack of blinding, which may introduce bias, and the fact that the primary outcome was negative. The study population was limited to those with depression for 3 months or longer, and the setting was US-based clinics, which may limit generalizability. Additionally, the effectiveness of pharmacogenetics to guide prescribing of SSRIs for depression remains unclear, as stated by the authors.

Clinically, these findings do not support routine use of genotype-guided SSRI prescribing for short-term symptom improvement. However, the higher remission rate at 6 months suggests a possible delayed benefit that warrants further investigation. For now, clinicians should not change practice based on this single trial, but may consider discussing pharmacogenetic testing with patients who have not responded to initial therapy, while acknowledging the uncertainty.

Several questions remain unanswered: Which specific genetic variants are most predictive? Is the benefit consistent across different SSRIs? Are there subgroups that derive greater benefit? What is the cost-effectiveness? Future studies should focus on longer-term outcomes and include diverse populations.